カテゴリー： MarketsandMarkets, 世界, 医療/バイオ

世界の体外診断（IVD）市場：製品＆サービス別（機器、キット、ソフトウェア）、技術別、用途別、エンドユーザー別

◆英語タイトル：In Vitro Diagnostics Market by Product and Service (Instruments, Kits, Software), Technology (Immunoassay, Hematology, Urinalysis), Application (Diabetes, Oncology, Cardiology, Infectious Disease), End User (Hospitals, Clinics) - Forecast to 2027

MarketsandMarketsが発行した調査報告書（MD3609-23）◆商品コード：MD3609-23
◆発行会社（リサーチ会社）：MarketsandMarkets
◆発行日：2023年1月5日
◆ページ数：453
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆産業分野：医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧）USD4,950 ⇒換算￥752,400見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算￥1,010,800見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算￥1,238,800見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

MarketsandMarkets社では、世界の体外診断（IVD）市場規模が、2022年1,158億ドルから2027年1,447億ドルまで年平均4.6%成長すると予測しています。当調査資料は、体外診断（IVD）の世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品＆サービス別（試薬＆キット、機器、データ管理ソフトウェア、サービス）分析、技術別（イムノアッセイ／イムノケミストリー、臨床化学、分子診断、血液診断、その他）分析、用途別（糖尿病、腫瘍、心臓病、薬物検査/ファーマコゲノミクス）分析、エンドユーザー別（病院検査室、臨床検査室、ポイントオブケア（POC）検査センター、患者、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東/アフリカ）分析、競争状況など、以下の構成でまとめております。なお、当書には、Roche Diagnostics (Switzerland)、Danaher Corporation (US)、Abbott Laboratories (US)、Siemens Healthineers AG (Germany)、Sysmex Corporation (Japan)、Thermo Fisher Scientific、Inc (US)、Becton、Dickinson and Company (BD、US)などの主要企業情報が含まれています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要

・世界の体外診断（IVD）市場規模：製品＆サービス別
- 試薬＆キットの市場規模
- 機器の市場規模
- データ管理ソフトウェアの市場規模
- サービスの市場規模

・世界の体外診断（IVD）市場規模：技術別
- イムノアッセイ／イムノケミストリー技術の市場規模
- 臨床化学技術の市場規模
- 分子診断技術の市場規模
- 血液診断技術の市場規模
- その他技術の市場規模

・世界の体外診断（IVD）市場規模：用途別
- 糖尿病における市場規模
- 腫瘍における市場規模
- 心臓病における市場規模
- 薬物検査/ファーマコゲノミクスにおける市場規模

・世界の体外診断（IVD）市場規模：エンドユーザー別
- 病院検査室における市場規模
- 臨床検査室における市場規模
- ポイントオブケア（POC）検査センターにおける市場規模
- 患者における市場規模
- その他エンドユーザーにおける市場規模

・世界の体外診断（IVD）市場規模：地域別
- 北米の体外診断（IVD）市場規模
- ヨーロッパの体外診断（IVD）市場規模
- アジア太平洋の体外診断（IVD）市場規模
- 中南米の体外診断（IVD）市場規模
- 中東/アフリカの体外診断（IVD）市場規模

・競争状況
・企業情報

“in vitro市場は、2022年の1,158億米ドルから2027年には1,447億米ドルに達し、年平均成長率は4.6%と予測
病気の早期診断のためのポイントオブケア機器や迅速検査の採用が増加していること、早期診断と治療による予防的治療のための政府の取り組みや資金援助が増加していることが、市場の成長を促進しています。

“試薬・キット分野が最大シェア”
IVD市場は、製品・サービス別に、試薬・キット、機器、サービス、データ管理ソフトウェアに区分されます。2021年のIVD市場で最大のシェアを占めたのは試薬・キット部門です。病気の検査やモニタリングのために、様々なハンドヘルド型や複雑なラボ用IVD機器で試薬が繰り返し使用されることが、このセグメントの成長を促進する主な要因です。

“免疫測定/免疫化学分野がIVD技術市場で最大シェアを占める”
IVD市場は技術別に、免疫測定/免疫化学、臨床化学、分子診断、血液学、微生物学、凝固・止血、尿検査、その他の技術に区分されます。2021年のIVD技術市場で最大のシェアを占めたのは免疫測定/免疫化学分野。免疫測定法は、他の診断法よりも免疫診断技術として好まれており、その理由は、これらの検査が迅速な結果を提供できること、最小限の人的介入で簡便なサンプル調製が必要であることです。

“感染症分野がIVD市場で最大のシェアを占める”
IVD市場はアプリケーションに基づいて、感染症、糖尿病、腫瘍学、循環器学、薬物検査/ファーマコゲノミクス、HIV/AIDS、自己免疫疾患、腎臓学、その他のアプリケーションに区分されます。2021年には、感染症分野がIVD市場で最大のシェアを占めました。このセグメントの大きなシェアは、多剤耐性感染症の流行増加に伴い、効果的な診断ツールに対するニーズが高まっていることに起因しています。

“予測期間中に最も高い成長を記録するPOC検査”
IVD市場はエンドユーザーに基づき、病院検査室、臨床検査室、学術機関、POC（ポイントオブケア）検査センター、患者、その他のエンドユーザーに区分されます。予測期間中に最も高いCAGRを記録するのはポイントオブケア分野です。この市場の成長は、遠隔地での検査や疾患の早期診断に対するニーズの高まりによるものです。さらに、ポイントオブケア検査の技術的進歩により、より信頼性が高く正確な検査が可能となり、この市場の成長を牽引しています。

“予測期間中、APACが最も高いCAGRで成長する見込み”
アジア太平洋地域のIVD市場は、予測期間中に最も高いCAGRを記録すると予測されています。同地域の成長の背景には、より良い医療サービスに対する需要の高まり、新興市場の医療インフラの急速な発展、予防医療手法に対する政府のイニシアチブの高まりがあります。

本レポートで参照した体外診断（IVD）市場の主要参入企業の内訳は以下の通りです：
– 企業タイプ別 企業タイプ別：Tier 1-35%、Tier 2-45%、Tier 3-20％
– 役職別 Cレベル-35%、ディレクターレベル-25%、その他-40％
– 地域別 北米-45%、欧州-30%、アジア太平洋地域-20%、ラテンアメリカ-3%、中東・アフリカ-2％

世界の体外診断（IVD）市場における主なプレーヤーは、Roche Diagnostics (Switzerland), Danaher Corporation (US), Abbott Laboratories (US), Siemens Healthineers AG (Germany), Sysmex Corporation (Japan), Thermo Fisher Scientific, Inc (US), Becton, Dickinson and Company (BD, US), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Netherlands), Quidel Corporation (US), bioMérieux SA (France), Agilent Technologies, Inc. (US), Chembio Diagnostics, Inc. (US), DiaSorin S.p.A (Italy), Illumina, Inc. (US), Hologic, Inc. (US), Devyser (Sweden), PerkinElmer Inc. (US), Surmodics, Inc. (US), Menarini Silicon Biosystems (Italy), SpeeDx Pty. Ltd. (Australia), GENSPEED Biotech GmbH (Austria), Accelerate Diagnostics, Inc. (US), Merck KGaA (Germany), and Caris Life Sciences Inc. (US)です。

調査範囲
本レポートでは、各種体外診断（IVD）用製品・サービスの市場およびその導入パターンを分析しています。体外診断（IVD）市場の市場規模や今後の成長性、技術別、用途別、エンドユーザー別、地域別などさまざまなセグメントを推定することを目的としています。また、同市場における主要企業の会社概要、サービス、最新動向など、詳細な競合分析も掲載しています。

レポート購入の理由
本レポートは、既存企業だけでなく、新規参入企業や小規模企業も市場の動向を把握するのに役立ち、ひいては、より大きなシェアを獲得するのに役立ちます。本レポートを購入された企業は、市場での存在感を高めるために、以下の5つの戦略のいずれか、または任意の組み合わせを使用することができます。

本レポートでは、以下のポイントに関する洞察を提供しています：
– 市場参入： 世界の体外診断（IVD）市場におけるトップ企業が提供するサービスポートフォリオに関する包括的な情報。
– サービス開発/イノベーション： 世界の体外診断（IVD）市場における今後の動向やサービス開始に関する詳細な洞察。
– 市場開発： 製品・サービス、技術、用途、エンドユーザー、地域別の有利な新興地域に関する包括的情報。
– 市場の多様化： 世界の体外診断（IVD）市場における新製品・サービス、成長地域、最新動向に関する網羅的な情報を提供。
– 競合評価： 世界の体外診断（IVD）市場における主要企業の市場シェア、成長戦略、収益分析、製品に関する詳細な評価。

❖ レポートの目次 ❖

1 INTRODUCTION 43
1.1 STUDY OBJECTIVES 43
1.2 MARKET DEFINITION 43
1.2.1 INCLUSIONS & EXCLUSIONS 44
1.2.2 MARKET SEGMENTATION 45
FIGURE 1 IN VITRO DIAGNOSTICS MARKET SEGMENTATION 45
1.2.3 YEARS CONSIDERED 46
1.3 CURRENCY CONSIDERED 46
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 46
1.4 STAKEHOLDERS 47
1.5 SUMMARY OF CHANGES 47
2 RESEARCH METHODOLOGY 48
2.1 RESEARCH APPROACH 48
FIGURE 2 RESEARCH DESIGN 48
2.1.1 SECONDARY RESEARCH 48
2.1.1.1 Key data from secondary sources 49
2.1.2 PRIMARY RESEARCH 50
2.1.2.1 Primary sources 50
2.1.2.2 Key data from primary sources 51
2.1.2.3 Key industry insights 51
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 52
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY-SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 52
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND-SIDE): BY END USER, DESIGNATION, AND REGION 53
2.2 MARKET SIZE ESTIMATION 53
FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2021) 54
FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION: ROCHE DIAGNOSTICS (2021) 54
FIGURE 8 SUPPLY-SIDE ANALYSIS: IN VITRO DIAGNOSTICS MARKET (2021) 55
FIGURE 9 IVD MARKET: TOP-DOWN APPROACH 56
FIGURE 10 CAGR PROJECTIONS FROM THE ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES & CHALLENGES OF THE
IVD INDUSTRY (2022–2027) 57
FIGURE 11 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS OF THE IN VITRO DIAGNOSTICS MARKET 57
2.3 DATA TRIANGULATION APPROACH 59
FIGURE 12 DATA TRIANGULATION METHODOLOGY 59
2.4 MARKET SHARE ESTIMATION 60
2.5 STUDY ASSUMPTIONS 60
2.6 LIMITATIONS 60
2.6.1 METHODOLOGY-RELATED LIMITATIONS 60
2.6.2 SCOPE-RELATED LIMITATIONS 60
2.7 RISK ASSESSMENT 61
TABLE 2 RISK ASSESSMENT: IN VITRO DIAGNOSTICS MARKET 61
3 EXECUTIVE SUMMARY 62
FIGURE 13 IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2022 VS. 2027 (USD MILLION) 62
FIGURE 14 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022 VS. 2027 (USD MILLION) 63
FIGURE 15 IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,
2022 VS. 2027 (USD MILLION) 63
FIGURE 16 IN VITRO DIAGNOSTICS MARKET, BY END USER,
2022 VS. 2027 (USD MILLION) 64
FIGURE 17 GEOGRAPHIC SNAPSHOT OF IVD MARKET 65
4 PREMIUM INSIGHTS 66
4.1 IN VITRO DIAGNOSTICS MARKET OVERVIEW 66
FIGURE 18 RISING INCIDENCE OF INFECTIOUS DISEASES AND GROWING ADOPTION OF TECHNOLOGICALLY ADVANCED ANALYZERS TO DRIVE MARKET 66
4.2 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE AND COUNTRY (2021) 67
FIGURE 19 REAGENTS & KITS SEGMENT ACCOUNTED FOR LARGEST SHARE IN 2021 67
4.3 IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 68
FIGURE 20 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 68
4.4 IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC MIX 68
FIGURE 21 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 68
4.5 IN VITRO DIAGNOSTICS MARKET: EMERGING VS. DEVELOPED MARKETS 69
FIGURE 22 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD 69
5 MARKET OVERVIEW 70
5.1 INTRODUCTION 70
5.2 MARKET DYNAMICS 70
FIGURE 23 IN VITRO DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 70
5.2.1 DRIVERS 71
5.2.1.1 Increasing geriatric population and subsequent rise in chronic & infectious diseases 71
TABLE 3 ESTIMATED INCREASE IN GERIATRIC POPULATION, BY REGION (2019–2050) 71
5.2.1.2 Gradual shift from centralized testing to point-of-care testing 72
5.2.1.3 Growing awareness of early disease diagnosis in emerging economies 72
5.2.1.4 Emergence of rapid PoC technologies and rising adoption of automated analyzers 73
TABLE 4 IN VITRO DIAGNOSTICS MARKET: PRODUCT LAUNCHES (2020−2022) 73
5.2.2 RESTRAINTS 74
5.2.2.1 Unfavorable reimbursement scenario 74
5.2.3 OPPORTUNITIES 74
5.2.3.1 Introduction of disease-specific biomarkers and tests 74
TABLE 5 APPLICATION OF CANCER BIOMARKERS IN CLINICAL PRACTICE 75
5.2.3.2 Growing significance of companion diagnostics 75
5.2.3.3 Growth opportunities in emerging markets 76
TABLE 6 RECENT DEVELOPMENTS IN EMERGING MARKETS 76
5.2.4 CHALLENGES 77
5.2.4.1 Stringent regulatory & legal guidelines 77
FIGURE 24 IVDR: KEY AREAS OF IMPACT 77
5.2.4.2 Operational barriers 78
TABLE 7 IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 78
5.3 INDUSTRY TRENDS 79
5.3.1 AUTOMATION OF CLINICAL LABORATORY TECHNIQUES 79
5.3.2 MICROFLUIDICS-BASED POC AND LAB-ON-A-CHIP DIAGNOSTIC DEVICES FOR LABORATORY TESTING 79
5.3.3 RISING NUMBER OF REAGENT RENTAL AGREEMENTS 80
5.3.4 REVENUE SOURCES TO SHIFT TOWARD TECHNOLOGY-BASED SOLUTIONS 80
FIGURE 25 REVENUE SOURCES TO SHIFT TOWARD TECHNOLOGY-BASED SOLUTIONS 80
5.4 PORTER’S FIVE FORCES ANALYSIS 81
TABLE 8 PORTER’S FIVE FORCES ANALYSIS: IN VITRO DIAGNOSTICS MARKET 81
5.4.1 INTENSITY OF COMPETITIVE RIVALRY 81
5.4.2 BARGAINING POWER OF SUPPLIERS 81
5.4.3 BARGAINING POWER OF BUYERS 81
5.4.4 THREAT OF NEW ENTRANTS 81
5.4.5 THREAT FROM SUBSTITUTES 82
5.5 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82
TABLE 9 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82
5.6 REGULATORY ANALYSIS 83
5.6.1 NORTH AMERICA 83
5.6.1.1 US 83
TABLE 10 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES 83
FIGURE 26 US: REGULATORY PROCESS FOR IVD DEVICES 84
5.6.1.2 Canada 85
FIGURE 27 CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA 85
5.6.2 EUROPE 85
TABLE 11 EUROPE: CLASSIFICATION OF IVD DEVICES 86
FIGURE 28 EUROPE: IVDR TIMELINE 86

5.6.3 ASIA PACIFIC 87
5.6.3.1 Japan 87
FIGURE 29 REGULATORY PROCESS FOR IVD DEVICES IN JAPAN 87
TABLE 12 JAPAN: CLASSIFICATION OF IVD REAGENTS IN JAPAN 88
TABLE 13 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 88
5.6.3.2 China 88
TABLE 14 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 88
5.6.3.3 India 89
FIGURE 30 INDIA: REGULATORY PROCESS FOR IVD DEVICES 89
5.6.3.4 South Korea 89
TABLE 15 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 89
5.6.3.5 Indonesia 90
TABLE 16 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES 90
5.6.4 RUSSIA 90
TABLE 17 RUSSIA: CLASSIFICATION OF IVD DEVICES 91
5.6.5 MIDDLE EAST & AFRICA 91
5.6.5.1 Saudi Arabia 91
TABLE 18 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 91
5.6.5.2 Africa 91
5.6.6 LATIN AMERICA 92
5.6.6.1 Mexico 92
FIGURE 31 MEXICO: REGULATORY PROCESS FOR IVD DEVICES 92
TABLE 19 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 93
5.6.6.2 Brazil 93
5.7 KEY CONFERENCES & EVENTS IN 2023 94
TABLE 20 IN VITRO DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES & EVENTS 94
5.8 PATENT ANALYSIS 95
5.8.1 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 95
FIGURE 32 TOP PATENT OWNERS AND APPLICANTS: IN VITRO DIAGNOSTICS MARKET (JANUARY 2011–DECEMBER 2022) 95
FIGURE 33 TOP APPLICANT JURISDICTIONS FOR IVD PATENTS
(JANUARY 20211-DECEMBER 2022) 96
5.8.2 PATENT PUBLICATION TRENDS FOR IN VITRO DIAGNOSTICS MARKET 96
FIGURE 34 PATENT ANALYSIS: IN VITRO DIAGNOSTICS MARKET
(JANUARY 2011–DECEMBER 2022) 96
TABLE 21 LIST OF PATENTS/PATENT APPLICATIONS IN IVD MARKET, 2021–2022 97
5.9 TRADE ANALYSIS 98
5.9.1 TRADE ANALYSIS FOR DIAGNOSTICS AND LABORATORY REAGENTS 98
TABLE 22 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY 2017-2021 (USD MILLION) 98
TABLE 23 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY 2017-2021 (TONS) 98

5.10 ECOSYSTEM ANALYSIS 98
FIGURE 35 ECOSYSTEM ANALYSIS: IN VITRO DIAGNOSTICS MARKET 99
5.10.1 IN VITRO DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM 99
5.11 VALUE CHAIN ANALYSIS 100
FIGURE 36 VALUE CHAIN ANALYSIS: IN VITRO DIAGNOSTICS MARKET 100
5.12 SUPPLY CHAIN ANALYSIS 101
FIGURE 37 SUPPLY CHAIN ANALYSIS: IN VITRO DIAGNOSTICS MARKET 101
5.13 PRICING ANALYSIS 102
5.13.1 INDICATIVE AVERAGE SELLING PRICE (USD) REGION-WISE: REAGENTS & KITS 102
5.13.2 AVERAGE SELLING PRICE (USD): IMMUNOASSAY ANALYZERS 102
5.13.3 AVERAGE SELLING PRICE (USD): LATERAL FLOW ANALYZERS 102
5.13.4 AVERAGE SELLING PRICE (USD): MOLECULAR DIAGNOSTICS 103
5.14 TECHNOLOGY ANALYSIS 104
5.14.1 KEY TECHNOLOGIES: IN VITRO DIAGNOSTICS MARKET 104
5.14.2 ADJACENT TECHNOLOGIES: IN VITRO DIAGNOSTICS MARKET 105
5.15 CASE STUDY 106
FIGURE 38 CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOUR IN INDIA 106
5.16 KEY STAKEHOLDERS & BUYING CRITERIA 107
5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS 107
FIGURE 39 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF IN VITRO DIAGNOSTIC PRODUCTS 107
TABLE 24 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF IN VITRO DIAGNOSTIC PRODUCTS (%) 107
5.16.2 BUYING CRITERIA 108
FIGURE 40 KEY BUYING CRITERIA FOR IN VITRO DIAGNOSTIC PRODUCTS 108
TABLE 25 KEY BUYING CRITERIA FOR IN VITRO DIAGNOSTIC PRODUCTS 108
5.17 IMPACT OF RECESSION ON IVD MARKET (2021–2024) 108
5.18 IMPACT OF IN VITRO DIAGNOSTIC REGULATIONS (IVDR) ON LABORATORY TESTING 109
6 IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 111
6.1 INTRODUCTION 112
TABLE 26 IN VITRO DIAGNOSTIC MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 112
6.2 REAGENTS & KITS 112
6.2.1 GROWING DEMAND FOR RAPID AND POINT-OF-CARE DIAGNOSTICS TO DRIVE MARKET 112
TABLE 27 IVD MARKET FOR REAGENTS & KITS, BY COUNTRY,
2020–2027 (USD MILLION) 114
6.3 INSTRUMENTS 114
TABLE 28 KEY INSTRUMENTS AVAILABLE IN IVD MARKET 115
TABLE 29 IVD MARKET FOR INSTRUMENTS, BY TYPE, 2020–2027 (USD MILLION) 116
TABLE 30 IVD MARKET FOR INSTRUMENTS, BY COUNTRY, 2020–2027 (USD MILLION) 116
6.3.1 FULLY AUTOMATED INSTRUMENTS 117
6.3.1.1 Rising availability of technologically advanced analyzers to drive market 117
TABLE 31 IVD MARKET FOR FULLY AUTOMATED INSTRUMENTS, BY COUNTRY,
2020–2027 (USD MILLION) 118
6.3.2 SEMI-AUTOMATED INSTRUMENTS 118
6.3.2.1 Compact design and cost-effectiveness over automated analyzers to support market growth 118
TABLE 32 IVD MARKET FOR SEMIAUTOMATED INSTRUMENTS, BY COUNTRY,
2020–2027 (USD MILLION) 119
6.3.3 OTHER INSTRUMENTS 119
TABLE 33 IVD MARKET FOR OTHER INSTRUMENTS, BY COUNTRY,
2020–2027 (USD MILLION) 120
6.4 DATA MANAGEMENT SOFTWARE 120
6.4.1 GROWING ADOPTION OF AUTOMATED ANALYZERS AND RISING NEED FOR EFFECTIVE DATA MANAGEMENT TO DRIVE MARKET 120
TABLE 34 KEY DATA MANAGEMENT SOFTWARE SOLUTIONS AVAILABLE IN IVD MARKET 121
TABLE 35 IVD MARKET FOR DATA MANAGEMENT SOFTWARE, BY COUNTRY,
2020–2027 (USD MILLION) 122
6.5 SERVICES 122
6.5.1 RISING NEED TO ENSURE EFFECTIVE UTILISATION OF IVD PRODUCTS TO SUPPORT MARKET GROWTH 122
TABLE 36 IVD MARKET FOR SERVICES, BY COUNTRY, 2020–2027 (USD MILLION) 123
7 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY 124
7.1 INTRODUCTION 125
TABLE 37 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY,
2020–2027 (USD MILLION) 125
7.2 IMMUNOASSAY/IMMUNOCHEMISTRY 125
TABLE 38 KEY IMMUNOASSAY/IMMUNOCHEMISTRY ANALYZERS AVAILABLE IN IVD MARKET 126
TABLE 39 IVD MARKET FOR IMMUNOASSAY/IMMUNOCHEMISTRY TECHNOLOGY,
BY TYPE, 2020–2027 (USD MILLION) 127
TABLE 40 IVD MARKET FOR IMMUNOASSAY/IMMUNOCHEMISTRY TECHNOLOGY,
BY COUNTRY, 2020–2027 (USD MILLION) 127
7.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA) 128
TABLE 41 KEY ELISA ANALYZERS AVAILABLE IN IVD MARKET 128
TABLE 42 IVD MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION) 129
TABLE 43 IVD MARKET FOR ELISA, BY COUNTRY, 2020–2027 (USD MILLION) 130
7.2.1.1 Chemiluminescence Immunoassays 130
7.2.1.1.1 Rising technological advancements and continuous product innovations to drive segment growth 130
TABLE 44 KEY CHEMILUMINESCENCE IMMUNOASSAY SYSTEMS AVAILABLE IN IVD MARKET 131
TABLE 45 IVD MARKET FOR CHEMILUMINESCENCE IMMUNOASSAYS, BY COUNTRY, 2020–2027 (USD MILLION) 132

7.2.1.2 Fluorescence Immunoassays 132
7.2.1.2.1 Rising demand for low-cost fluorescent dyes to drive segment growth 132
TABLE 46 KEY FLUORESCENCE IMMUNOASSAY SYSTEMS AVAILABLE IN IVD MARKET 133
TABLE 47 IVD MARKET FOR FLUORESCENCE IMMUNOASSAYS, BY COUNTRY,
2020–2027 (USD MILLION) 134
7.2.1.3 Colorimetric Immunoassays 134
7.2.1.3.1 High specificity and easy coagulation to antibodies to drive segment growth 134
TABLE 48 KEY COLORIMETRIC IMMUNOASSAY SYSTEMS AVAILABLE IN IVD MARKET 135
TABLE 49 IVD MARKET FOR COLORIMETRIC IMMUNOASSAYS, BY COUNTRY,
2020–2027 (USD MILLION) 135
7.2.2 RADIOIMMUNOASSAYS 136
7.2.2.1 Usage of RIAs in cancer detection, blood screening, and drug discovery to drive market 136
TABLE 50 IVD MARKET FOR RADIOIMMUNOASSAYS, BY COUNTRY,
2020–2027 (USD MILLION) 136
7.2.3 RAPID TESTS 137
7.2.3.1 Rising usage of rapid tests for emergency care to drive market 137
TABLE 51 KEY RAPID TESTS AVAILABLE IN IVD MARKET 137
TABLE 52 IVD MARKET FOR RAPID TESTS, BY COUNTRY, 2020–2027 (USD MILLION) 138
7.2.4 WESTERN BLOTTING 138
7.2.4.1 Widely accepted technique for result validation to support market growth 138
TABLE 53 KEY WESTERN BLOTTING SYSTEMS AVAILABLE IN IVD MARKET 139
TABLE 54 IVD MARKET FOR WESTERN BLOTTING, BY COUNTRY,
2020–2027 (USD MILLION) 139
7.2.5 ENZYME-LINKED IMMUNOSPOT ASSAYS (ELISPOT) 140
7.2.5.1 High sensitivity and adaptability of technology to fuel market adoption 140
TABLE 55 IVD MARKET FOR ELISPOT ASSAYS, BY COUNTRY,
2020–2027 (USD MILLION) 140
7.3 CLINICAL CHEMISTRY 141
TABLE 56 CLINICAL CHEMISTRY ANALYZERS FOR HIGH AND MID-VOLUME LABORATORIES 141
TABLE 57 CLINICAL CHEMISTRY ANALYZERS FOR LOW-VOLUME LABORATORIES 142
TABLE 58 KEY BLOOD GAS ANALYZERS AVAILABLE IN IVD MARKET 143
TABLE 59 IVD MARKET FOR CLINICAL CHEMISTRY, BY TYPE,
2020–2027 (USD MILLION) 144
TABLE 60 CLINICAL CHEMISTRY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 144
7.3.1 BASIC METABOLIC PANELS 145
7.3.1.1 Set of blood tests performed to ascertain common acute conditions 145
TABLE 61 IVD MARKET FOR BASIC METABOLIC PANELS, BY COUNTRY,
2020–2027 (USD MILLION) 145
7.3.2 LIVER PANELS 146
7.3.2.1 Panels used to identify and monitor liver diseases & injuries 146
TABLE 62 IVD MARKET FOR LIVER PANELS, BY COUNTRY, 2020–2027 (USD MILLION) 146
7.3.3 RENAL PROFILES 147
7.3.3.1 Panels used to monitor cytokines & chemokines in urine 147
TABLE 63 IVD MARKET FOR RENAL PROFILES, BY COUNTRY,
2020–2027 (USD MILLION) 147
7.3.4 LIPID PROFILES 148
7.3.4.1 Lipid panel testing determines total cholesterol and risk status for CVD 148
TABLE 64 IVD MARKET FOR LIPID PROFILES, BY COUNTRY,
2020–2027 (USD MILLION) 148
7.3.5 THYROID FUNCTION PANELS 149
7.3.5.1 Tests performed to determine TSH and thyroglobulin 149
TABLE 65 IVD MARKET FOR THYROID FUNCTION PANELS, BY COUNTRY,
2020–2027 (USD MILLION) 149
7.3.6 ELECTROLYTE PANELS 150
7.3.6.1 Prescribed for symptoms such as edema, nausea, and cardiac arrhythmia 150
TABLE 66 IVD MARKET FOR ELECTROLYTE PANELS, BY COUNTRY,
2020–2027 (USD MILLION) 150
7.3.7 SPECIALTY CHEMICAL TESTS 151
7.3.7.1 Test profile includes immunosuppressant drug monitoring and drugs of abuse 151
TABLE 67 IVD MARKET FOR SPECIALTY CHEMICAL TESTS, BY COUNTRY,
2020–2027 (USD MILLION) 151
7.4 MOLECULAR DIAGNOSTICS 152
TABLE 68 KEY AUTOMATED MOLECULAR DIAGNOSTIC PLATFORMS AVAILABLE IN IVD MARKET 152
TABLE 69 IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE,
2020–2027 (USD MILLION) 153
TABLE 70 IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY,
2020–2027 (USD MILLION) 154
7.4.1 POLYMERASE CHAIN REACTION (PCR) 154
7.4.1.1 Rising prevalence of infectious & viral diseases to drive market 154
TABLE 71 KEY PCR INSTRUMENTS AVAILABLE IN IVD MARKET 155
TABLE 72 IVD MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY,
2020–2027 (USD MILLION) 156
7.4.2 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT) 156
7.4.2.1 Growing popularity of INAAT and NAAT for infectious disease diagnostics to support market growth 156
TABLE 73 IVD MARKET FOR INAAT, BY COUNTRY, 2020–2027 (USD MILLION) 157
7.4.3 HYBRIDIZATION 157
7.4.3.1 Advanced hybridization & automation of data collection techniques to support market growth 157
TABLE 74 IVD MARKET FOR HYBRIDIZATION, BY COUNTRY, 2020–2027 (USD MILLION) 158
7.4.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING (NGS) 158
7.4.4.1 Rising demand for personalized medicine to support market growth 158
TABLE 75 KEY NGS INSTRUMENTS AVAILABLE IN IVD MARKET 159
TABLE 76 IVD MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY,
2020–2027 (USD MILLION) 160
7.4.5 MICROARRAYS 160
7.4.5.1 High throughput & resolution capabilities to drive market for protein expression profiling 160
TABLE 77 IVD MARKET FOR MICROARRAYS, BY COUNTRY, 2020–2027 (USD MILLION) 161
7.4.6 OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES 162
TABLE 78 IVD MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES,
BY COUNTRY, 2020–2027 (USD MILLION) 162
7.5 HEMATOLOGY 163
7.5.1 INCREASING ADOPTION OF AUTOMATED HEMATOLOGY ANALYZERS TO DRIVE MARKET 163
TABLE 79 KEY HEMATOLOGY ANALYZERS AVAILABLE IN IVD MARKET 163
TABLE 80 IVD MARKET FOR HEMATOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 164
7.6 MICROBIOLOGY 165
7.6.1 RISING PREVALENCE OF MICROBIAL INFECTIONS TO FUEL MARKET 165
TABLE 81 KEY MICROBIOLOGY INSTRUMENTS AVAILABLE IN IVD MARKET 165
TABLE 82 IVD MARKET FOR MICROBIOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 166
7.7 COAGULATION & HEMOSTASIS 167
7.7.1 GROWING USE OF ANTICOAGULATION THERAPY IN SURGICAL PROCEDURES TO DRIVE MARKET 167
TABLE 83 KEY COAGULATION ANALYZERS AVAILABLE IN IVD MARKET 167
TABLE 84 KEY POINT-OF-CARE/SELF-MONITORING COAGULATION ANALYZERS AVAILABLE IN IVD MARKET 168
TABLE 85 IVD MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY,
2020–2027 (USD MILLION) 169
7.8 URINALYSIS 169
7.8.1 RISING PREVALENCE OF KIDNEY DISORDERS AND UTIS TO DRIVE MARKET 169
TABLE 86 KEY URINALYSIS INSTRUMENTS AVAILABLE IN IVD MARKET 170
TABLE 87 IVD MARKET FOR URINALYSIS, BY COUNTRY, 2020–2027 (USD MILLION) 171
7.9 OTHER TECHNOLOGIES 171
TABLE 88 KEY BLOOD GLUCOSE TESTING SYSTEMS AVAILABLE IN IVD MARKET 172
TABLE 89 TISSUE PROCESSORS, EMBEDDERS, MICROTOMES, AND STAINERS AVAILABLE IN IVD MARKET 172
TABLE 90 IVD MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY,
2020–2027 (USD MILLION) 173
8 IN VITRO DIAGNOSTICS MARKET, BY APPLICATION 174
8.1 INTRODUCTION 175
TABLE 91 IN VITRO DIAGNOSTICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 175
8.2 INFECTIOUS DISEASES 175
8.2.1 INCREASING INCIDENCE OF INFECTIOUS DISEASES TO DRIVE ADOPTION OF IVD PRODUCTS 175
TABLE 92 IVD MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,
2020–2027 (USD MILLION) 176
8.3 DIABETES 177
8.3.1 RISING PREVALENCE OF DIABETES TO DRIVE ADOPTION OF GLUCOSE MONITORING DEVICES 177
TABLE 93 COUNTRIES WITH A DIABETIC PATIENT POPULATION,
2021 VS. 2045 (MILLION) 177
TABLE 94 IVD MARKET FOR DIABETES, BY COUNTRY, 2020–2027 (USD MILLION) 178
8.4 ONCOLOGY 178
8.4.1 RISING INITIATIVES FOR EARLY DETECTION OF CANCER TO DRIVE MARKET 178
TABLE 95 IVD MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 179
8.5 CARDIOLOGY 180
8.5.1 INCREASING USE OF IMMUNOASSAYS IN DETECTION OF CVD TO DRIVE MARKET 180
TABLE 96 IVD MARKET FOR CARDIOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 181
8.6 DRUG TESTING/PHARMACOGENOMICS 181
8.6.1 INCREASING USE OF TOXICOLOGY TESTING FOR ILLICIT DRUGS TO DRIVE MARKET 181
TABLE 97 IVD MARKET FOR DRUG TESTING/PHARMACOGENOMICS, BY COUNTRY, 2020–2027 (USD MILLION) 182
8.7 HIV/AIDS 182
8.7.1 INCREASING USAGE OF REAL-TIME PCR TESTS FOR HIV DETECTION TO DRIVE MARKET 182
TABLE 98 IVD MARKET FOR HIV/AIDS, BY COUNTRY, 2020–2027 (USD MILLION) 183
8.8 AUTOIMMUNE DISEASES 183
8.8.1 GROWING DEMAND FOR PORTABLE POC DIAGNOSTIC DEVICES TO DRIVE MARKET 183
TABLE 99 IVD MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY,
2020–2027 (USD MILLION) 184
8.9 NEPHROLOGY 185
8.9.1 INCREASING USE OF BIOMARKERS FOR CKD TO SUPPORT MARKET GROWTH 185
TABLE 100 IVD MARKET FOR NEPHROLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 186
8.10 OTHER APPLICATIONS 186
TABLE 101 IVD MARKET FOR OTHER APPLICATIONS, BY COUNTRY,
2020–2027 (USD MILLION) 187
9 IN VITRO DIAGNOSTICS MARKET, BY END USER 188
9.1 INTRODUCTION 189
TABLE 102 IN-VITRO DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 189
9.2 HOSPITAL LABORATORIES 189
9.2.1 RISING NUMBER OF HOSPITALIZATIONS DUE TO INCREASING INFECTIOUS DISEASES TO DRIVE MARKET 189
TABLE 103 IVD MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY,
2020–2027 (USD MILLION) 191

9.3 CLINICAL LABORATORIES 191
TABLE 104 IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION) 192
TABLE 105 IVD MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION) 192
9.3.1 LARGE REFERENCE LABORATORIES 193
9.3.1.1 Capability to conduct specific tests such as LDTs with advanced diagnostic tools to drive segment growth 193
TABLE 106 LARGE REFERENCE LABORATORIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 193
9.3.2 MEDIUM-SIZED LABORATORIES 194
9.3.2.1 Increasing adoption of automated instruments to drive growth of this segment 194
TABLE 107 MEDIUM-SIZED LABORATORIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 194
9.3.3 SMALL LABORATORIES 195
9.3.3.1 Adoption of point-of-care devices to support segment growth 195
TABLE 108 SMALL LABORATORIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 195
9.4 POINT-OF-CARE TESTING CENTERS 196
9.4.1 RISING DEMAND FOR RAPID TESTING AND AVAILABILITY OF INNOVATIVE POINT-OF-CARE IVD PRODUCTS TO DRIVE MARKET 196
TABLE 109 IVD MARKET FOR POINT-OF-CARE TESTING CENTERS, BY COUNTRY, 2020–2027 (USD MILLION) 197
9.5 PATIENTS 197
9.5.1 USE OF CONVENIENT SELF-TEST KITS TO DRIVE MARKET 197
TABLE 110 IVD MARKET FOR PATIENTS, BY COUNTRY, 2020–2027 (USD MILLION) 198
9.6 ACADEMIC INSTITUTES 199
9.6.1 RISING INDUSTRY-ACADEMIA COLLABORATIONS FOR PRODUCT DEVELOPMENT TO SUPPORT MARKET GROWTH 199
TABLE 111 IVD MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 199
9.7 OTHER END USERS 200
TABLE 112 IVD MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION) 201
10 IN VITRO DIAGNOSTICS MARKET, BY REGION 202
10.1 INTRODUCTION 203
FIGURE 41 IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC SNAPSHOT (2021) 203
TABLE 113 IN VITRO DIAGNOSTICS MARKET, BY REGION, 2020–2027 (USD MILLION) 204
10.2 NORTH AMERICA 204
FIGURE 42 NORTH AMERICA: IVD MARKET SNAPSHOT 205
TABLE 114 NORTH AMERICA: IVD MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 205
TABLE 115 NORTH AMERICA: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 206
TABLE 116 NORTH AMERICA: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 206
TABLE 117 NORTH AMERICA: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 207
TABLE 118 NORTH AMERICA: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 207
TABLE 119 NORTH AMERICA: IVD MARKET, BY END USER, 2020–2027 (USD MILLION) 208
TABLE 120 NORTH AMERICA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION) 208
10.2.1 US 208
10.2.1.1 Established reimbursement framework and favorable policies for IVD providers to drive market 208
TABLE 121 US: MACROECONOMIC INDICATORS 210
TABLE 122 US: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 210
TABLE 123 US: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 210
TABLE 124 US: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 211
TABLE 125 US: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 211
TABLE 126 US: IVD MARKET, BY END USER, 2020–2027 (USD MILLION) 212
TABLE 127 US: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION) 212
10.2.2 CANADA 212
10.2.2.1 Rising government initiatives & funding for early disease diagnosis to drive market 212
TABLE 128 CANADA: ESTIMATED PREVALENCE OF DIABETES 213
TABLE 129 CANADA: MACROECONOMIC INDICATORS 214
TABLE 130 CANADA: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 214
TABLE 131 CANADA: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 215
TABLE 132 CANADA: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 215
TABLE 133 CANADA: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 216
TABLE 134 CANADA: IVD MARKET, BY END USER, 2020–2027 (USD MILLION) 216
TABLE 135 CANADA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION) 217
10.3 EUROPE 217
TABLE 136 EUROPE: IVD MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 218
TABLE 137 EUROPE: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 218
TABLE 138 EUROPE: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 218
TABLE 139 EUROPE: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 219
TABLE 140 EUROPE: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 219
TABLE 141 EUROPE: IVD MARKET, BY END USER, 2020–2027 (USD MILLION) 220
TABLE 142 EUROPE: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION) 220
10.3.1 GERMANY 220
10.3.1.1 Growing investments in clinical diagnostics research to drive market 220
TABLE 143 GERMANY: MACROECONOMIC INDICATORS 221
TABLE 144 GERMANY: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 221
TABLE 145 GERMANY: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 222
TABLE 146 GERMANY: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 222
TABLE 147 GERMANY: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 223
TABLE 148 GERMANY: IVD MARKET, BY END USER, 2020–2027 (USD MILLION) 223
TABLE 149 GERMANY: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION) 224
10.3.2 FRANCE 224
10.3.2.1 High healthcare expenditure and rising investments in genomic medicine to drive market 224
TABLE 150 FRANCE: MACROECONOMIC INDICATORS 225
TABLE 151 FRANCE: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 225
TABLE 152 FRANCE: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 225
TABLE 153 FRANCE: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 226
TABLE 154 FRANCE: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 226
TABLE 155 FRANCE: IVD MARKET, BY END USER, 2020–2027 (USD MILLION) 227
TABLE 156 FRANCE: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION) 227
10.3.3 UK 227
10.3.3.1 Rising adoption of genome-based testing and increasing accessibility to IVD tests to drive market 227
TABLE 157 UK: MACROECONOMIC INDICATORS 228
TABLE 158 UK: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 229
TABLE 159 UK: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 229
TABLE 160 UK: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 230
TABLE 161 UK: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 230
TABLE 162 UK: IVD MARKET, BY END USER, 2020–2027 (USD MILLION) 231
TABLE 163 UK: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION) 231
10.3.4 ITALY 231
10.3.4.1 Growing geriatric population and subsequent rise in chronic conditions to support market growth 231
TABLE 164 ITALY: MACROECONOMIC INDICATORS 232
TABLE 165 ITALY: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 233
TABLE 166 ITALY: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 233
TABLE 167 ITALY: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 233
TABLE 168 ITALY: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 234
TABLE 169 ITALY: IVD MARKET, BY END USER, 2020–2027 (USD MILLION) 234
TABLE 170 ITALY: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION) 235
10.3.5 SPAIN 235
10.3.5.1 Rising adoption of technologically advanced immunoassay systems to drive market 235
TABLE 171 SPAIN: MACROECONOMIC INDICATORS 236
TABLE 172 SPAIN: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 236
TABLE 173 SPAIN: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 236
TABLE 174 SPAIN: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 237
TABLE 175 SPAIN: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 237
TABLE 176 SPAIN: IVD MARKET, BY END USER, 2020–2027 (USD MILLION) 238
TABLE 177 SPAIN: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION) 238
10.3.6 RUSSIA 238
10.3.6.1 Rising incidence of non-communicable diseases and government support for medical services to support market growth 238
TABLE 178 RUSSIA: MACROECONOMIC INDICATORS 239
TABLE 179 RUSSIA: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 239
TABLE 180 RUSSIA: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 240
TABLE 181 RUSSIA: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 240
TABLE 182 RUSSIA: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 241
TABLE 183 RUSSIA: IVD MARKET, BY END USER, 2020–2027 (USD MILLION) 241
TABLE 184 RUSSIA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION) 242
10.3.7 REST OF EUROPE 242
TABLE 185 REST OF EUROPE: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 242
TABLE 186 REST OF EUROPE: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 243
TABLE 187 REST OF EUROPE: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 243
TABLE 188 REST OF EUROPE: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 244
TABLE 189 REST OF EUROPE: IVD MARKET, BY END USER, 2020–2027 (USD MILLION) 244
TABLE 190 REST OF EUROPE: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION) 245
10.4 ASIA PACIFIC 245
FIGURE 43 ASIA PACIFIC: IVD MARKET SNAPSHOT 246
TABLE 191 ASIA PACIFIC: IVD MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 247
TABLE 192 ASIA PACIFIC: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 247
TABLE 193 ASIA PACIFIC: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 247
TABLE 194 ASIA PACIFIC: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 248
TABLE 195 ASIA PACIFIC: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 248
TABLE 196 ASIA PACIFIC: IVD MARKET, BY END USER, 2020–2027 (USD MILLION) 249
TABLE 197 ASIA PACIFIC: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION) 249
10.4.1 JAPAN 249
10.4.1.1 Universal healthcare reimbursement policy and research investments for immunoassays to support market growth 249
TABLE 198 JAPAN: MACROECONOMIC INDICATORS 250
TABLE 199 JAPAN: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 251
TABLE 200 JAPAN: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 251
TABLE 201 JAPAN: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)) 251
TABLE 202 JAPAN: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 252
TABLE 203 JAPAN: IVD MARKET, BY END USER, 2020–2027 (USD MILLION) 252
TABLE 204 JAPAN: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION) 253
10.4.2 CHINA 253
10.4.2.1 Increasing awareness of preventive care to drive market for advanced & rapid testing platforms 253
TABLE 205 CHINA: MACROECONOMIC INDICATORS 254
TABLE 206 CHINA: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 254
TABLE 207 CHINA: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 254
TABLE 208 CHINA: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 255
TABLE 209 CHINA: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 255
TABLE 210 CHINA: IVD MARKET, BY END USER, 2020–2027 (USD MILLION) 256
TABLE 211 CHINA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION) 256
10.4.3 INDIA 256
10.4.3.1 Rising incidence of diabetes and cancer to fuel market growth for IVD products 256
TABLE 212 INDIA: MACROECONOMIC INDICATORS 257
TABLE 213 INDIA: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 258
TABLE 214 INDIA: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 258
TABLE 215 INDIA: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 258
TABLE 216 INDIA: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 259
TABLE 217 INDIA: IVD MARKET, BY END USER, 2020–2027 (USD MILLION) 259
TABLE 218 INDIA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION) 260
10.4.4 SOUTH KOREA 260
10.4.4.1 Rising healthcare spending for innovative IVD technologies to support market growth 260
TABLE 219 SOUTH KOREA: MACROECONOMIC INDICATORS 261
TABLE 220 SOUTH KOREA: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 261
TABLE 221 SOUTH KOREA: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 261
TABLE 222 SOUTH KOREA: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 262
TABLE 223 SOUTH KOREA: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 262
TABLE 224 SOUTH KOREA: IVD MARKET, BY END USER, 2020–2027 (USD MILLION) 263
TABLE 225 SOUTH KOREA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION) 263

10.4.5 INDONESIA 263
10.4.5.1 Increasing healthcare initiatives and rising burden of infectious diseases to drive market 263
TABLE 226 INDONESIA: MACROECONOMIC INDICATORS 264
TABLE 227 INDONESIA: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 264
TABLE 228 INDONESIA: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 265
TABLE 229 INDONESIA: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 265
TABLE 230 INDONESIA: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 266
TABLE 231 INDONESIA: IVD MARKET, BY END USER, 2020–2027 (USD MILLION) 266
TABLE 232 INDONESIA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION) 267
10.4.6 REST OF ASIA PACIFIC 267
TABLE 233 REST OF ASIA PACIFIC: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 268
TABLE 234 REST OF ASIA PACIFIC: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 268
TABLE 235 REST OF ASIA PACIFIC: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 269
TABLE 236 REST OF ASIA PACIFIC: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 269
TABLE 237 REST OF ASIA PACIFIC: IVD MARKET, BY END USER, 2020–2027 (USD MILLION) 270
TABLE 238 REST OF ASIA PACIFIC: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION) 270
10.5 LATIN AMERICA 270
TABLE 239 LATIN AMERICA: IVD MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 271
TABLE 240 LATIN AMERICA: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 271
TABLE 241 LATIN AMERICA: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 271
TABLE 242 LATIN AMERICA: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 272
TABLE 243 LATIN AMERICA: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 272
TABLE 244 LATIN AMERICA: IVD MARKET, BY END USER, 2020–2027 (USD MILLION) 273
TABLE 245 LATIN AMERICA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION) 273
10.5.1 BRAZIL 273
10.5.1.1 Improving healthcare infrastructure to support adoption of IVD products 273
TABLE 246 BRAZIL: MACROECONOMIC INDICATORS 274
TABLE 247 BRAZIL: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 274
TABLE 248 BRAZIL: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 275
TABLE 249 BRAZIL: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 275
TABLE 250 BRAZIL: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 276
TABLE 251 BRAZIL: IVD MARKET, BY END USER, 2020–2027 (USD MILLION) 276
TABLE 252 BRAZIL: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION) 277
10.5.2 MEXICO 277
10.5.2.1 Improving accessibility and affordability to healthcare services to support market growth 277
TABLE 253 MEXICO: MACROECONOMIC INDICATORS 278
TABLE 254 MEXICO: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 278
TABLE 255 MEXICO: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 278
TABLE 256 MEXICO: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 279
TABLE 257 MEXICO: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 279
TABLE 258 MEXICO: IVD MARKET, BY END USER, 2020–2027 (USD MILLION) 280
TABLE 259 MEXICO: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION) 280
10.5.3 REST OF LATIN AMERICA 280
TABLE 260 REST OF LATIN AMERICA: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 281
TABLE 261 REST OF LATIN AMERICA: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 281
TABLE 262 REST OF LATIN AMERICA: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 282
TABLE 263 REST OF LATIN AMERICA: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 282
TABLE 264 REST OF LATIN AMERICA: IVD MARKET, BY END USER, 2020–2027 (USD MILLION)) 283
TABLE 265 REST OF LATIN AMERICA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION) 283
10.6 MIDDLE EAST & AFRICA 283
TABLE 266 MIDDLE EAST & AFRICA: IVD MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 284
TABLE 267 MIDDLE EAST & AFRICA: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 284
TABLE 268 MIDDLE EAST & AFRICA: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 284
TABLE 269 MIDDLE EAST & AFRICA: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 285
TABLE 270 MIDDLE EAST & AFRICA: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 285
TABLE 271 MIDDLE EAST & AFRICA: IVD MARKET, BY END USER, 2020–2027 (USD MILLION) 286
TABLE 272 MIDDLE EAST & AFRICA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION) 286
10.6.1 SAUDI ARABIA 286
10.6.1.1 Rising government healthcare expenditure to support adoption of IVD products 286
TABLE 273 SAUDI ARABIA: MACROECONOMIC INDICATORS 287
TABLE 274 SAUDI ARABIA: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 287
TABLE 275 SAUDI ARABIA: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 287
TABLE 276 SAUDI ARABIA: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 288
TABLE 277 SAUDI ARABIA: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 288
TABLE 278 SAUDI ARABIA: IVD MARKET, BY END USER, 2020–2027 (USD MILLION) 289
TABLE 279 SAUDI ARABIA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION) 289
10.6.2 REST OF MIDDLE EAST & AFRICA 289
TABLE 280 REST OF MIDDLE EAST & AFRICA: IVD MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 290
TABLE 281 REST OF MIDDLE EAST & AFRICA: IVD INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 290
TABLE 282 REST OF MIDDLE EAST & AFRICA: IVD MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 290
TABLE 283 REST OF MIDDLE EAST & AFRICA: IVD MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 291
TABLE 284 REST OF MIDDLE EAST & AFRICA: IVD MARKET, BY END USER, 2020–2027 (USD MILLION) 291
TABLE 285 REST OF MIDDLE EAST & AFRICA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2020–2027 (USD MILLION) 292
11 COMPETITIVE LANDSCAPE 293
11.1 OVERVIEW 293
11.2 STRATEGIES ADOPTED BY KEY PLAYERS 293
FIGURE 44 OVERVIEW OF STRATEGIES ADOPTED BY MAJOR PLAYERS IN IVD MARKET 294
11.3 REVENUE SHARE ANALYSIS OF KEY PLAYERS 295
FIGURE 45 REVENUE ANALYSIS FOR KEY PLAYERS IN IVD MARKET 295
11.4 MARKET SHARE ANALYSIS 296
FIGURE 46 IN VITRO DIAGNOSTICS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021) 296
TABLE 286 IN VITRO DIAGNOSTICS MARKET: DEGREE OF COMPETITION 297
11.4.1 MARKET SHARE ANALYSIS, BY TECHNOLOGY 298
11.4.1.1 Clinical chemistry 298
FIGURE 47 CLINICAL CHEMISTRY MARKET SHARE ANALYSIS, BY KEY PLAYER (2021) 298
11.4.1.2 Immunochemistry/immunoassay analyzers 299
FIGURE 48 IMMUNOASSAYS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021) 299
11.4.1.3 Microbiology 299
FIGURE 49 MICROBIOLOGY MARKET SHARE ANALYSIS, BY KEY PLAYER (2021) 299
11.4.1.4 Molecular diagnostics 300
FIGURE 50 MOLECULAR DIAGNOSTICS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021) 300
11.4.1.5 Hematology 300
FIGURE 51 HEMATOLOGY MARKET SHARE ANALYSIS, BY KEY PLAYER (2021) 300
11.4.1.6 Coagulation & hemostasis 301
FIGURE 52 COAGULATION & HEMOSTASIS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021) 301
11.4.1.7 Urinalysis 301
FIGURE 53 URINALYSIS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021) 301
11.5 R&D ASSESSMENT OF KEY PLAYERS 302
 
11.6 COMPETITIVE BENCHMARKING 302
TABLE 287 IN VITRO DIAGNOSTIC MARKET: DETAILED LIST OF SMALL & MEDIUM PLAYERS 302
11.7 COMPANY EVALUATION QUADRANT 303
11.7.1 STARS 303
11.7.2 PERVASIVE PLAYERS 303
11.7.3 EMERGING LEADERS 303
11.7.4 PARTICIPANTS 303
FIGURE 54 IN VITRO DIAGNOSTICS MARKET: COMPANY EVALUATION QUADRANT 2021 304
11.8 COMPANY EVALUATION QUADRANT FOR SMES/STARTUPS 304
11.8.1 PROGRESSIVE COMPANIES 304
11.8.2 DYNAMIC COMPANIES 304
11.8.3 STARTING BLOCKS 305
11.8.4 RESPONSIVE COMPANIES 305
FIGURE 55 IN VITRO DIAGNOSTICS MARKET: COMPANY EVALUATION QUADRANT FOR SMES & STARTUPS 305
11.9 COMPANY FOOTPRINT ANALYSIS 306
TABLE 288 IVD MARKET: COMPANY FOOTPRINT 306
TABLE 289 COMPANY FOOTPRINT: BY PRODUCT & SERVICE 307
TABLE 290 COMPANY FOOTPRINT: BY TECHNOLOGY 308
TABLE 291 COMPANY FOOTPRINT: BY APPLICATION 309
TABLE 292 COMPANY FOOTPRINT: BY END USER 310
11.10 COMPETITIVE SCENARIO 311
11.10.1 PRODUCT LAUNCHES & APPROVALS 311
TABLE 293 PRODUCT LAUNCHES & APPROVALS, JANUARY 2019–DECEMBER 2022 311
11.10.2 DEALS 312
TABLE 294 DEALS, JANUARY 2019–DECEMBER 2022 312
11.10.3 OTHER DEVELOPMENTS 313
TABLE 295 OTHER DEVELOPMENTS, JANUARY 2019–DECEMBER 2022 313
12 COMPANY PROFILES 314
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1 KEY PLAYERS 314
12.1.1 ROCHE DIAGNOSTICS 314
TABLE 296 ROCHE DIAGNOSTICS: BUSINESS OVERVIEW 314
FIGURE 56 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2021) 315
12.1.2 DANAHER CORPORATION 325
TABLE 297 DANAHER CORPORATION: BUSINESS OVERVIEW 325
FIGURE 57 DANAHER CORPORATION: COMPANY SNAPSHOT (2021) 326
12.1.3 ABBOTT LABORATORIES, INC. 333
TABLE 298 ABBOTT LABORATORIES: BUSINESS OVERVIEW 333
FIGURE 58 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021) 334
12.1.4 SIEMENS HEALTHINEERS 341
TABLE 299 SIEMENS HEALTHINEERS: BUSINESS OVERVIEW 341
FIGURE 59 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2021) 342
12.1.5 SYSMEX CORPORATION 348
TABLE 300 SYSMEX CORPORATION: BUSINESS OVERVIEW 348
FIGURE 60 SYSMEX CORPORATION: COMPANY SNAPSHOT (2021) 349
12.1.6 THERMO FISHER SCIENTIFIC, INC. 356
TABLE 301 THERMO FISHER SCIENTIFIC, INC: BUSINESS OVERVIEW 356
FIGURE 61 THERMO FISHER SCIENTIFIC, INC: COMPANY SNAPSHOT (2021) 357
12.1.7 BECTON, DICKINSON AND COMPANY 371
TABLE 302 BD: BUSINESS OVERVIEW 371
FIGURE 62 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021) 372
12.1.8 BIOMÉRIEUX SA 379
TABLE 303 BIOMÉRIEUX SA: BUSINESS OVERVIEW 379
FIGURE 63 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2021) 380
12.1.9 BIO-RAD LABORATORIES, INC. 385
TABLE 304 BIO-RAD LABORATORIES, INC: BUSINESS OVERVIEW 385
FIGURE 64 BIO-RAD LABORATORIES, INC: COMPANY SNAPSHOT (2021) 386
12.1.10 AGILENT TECHNOLOGIES, INC. 393
TABLE 305 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW 393
FIGURE 65 AGILENT TECHNOLOGIES, INC: COMPANY SNAPSHOT (2021) 394
12.1.11 QIAGEN N.V. 400
TABLE 306 QIAGEN N.V.: BUSINESS OVERVIEW 400
FIGURE 66 QIAGEN N.V.: COMPANY SNAPSHOT (2021) 401
12.1.12 QUIDEL CORPORATION 410
TABLE 307 QUIDEL CORPORATION: BUSINESS OVERVIEW 410
FIGURE 67 QUIDEL CORPORATION: COMPANY SNAPSHOT (2021) 411
12.1.13 DIASORIN S.P.A. 415
TABLE 308 DIASORIN S.P.A: BUSINESS OVERVIEW 415
FIGURE 68 DIASORIN S.P.A: COMPANY SNAPSHOT (2021) 416
12.1.14 ILLUMINA, INC. 424
TABLE 309 ILLUMINA, INC: BUSINESS OVERVIEW 424
FIGURE 69 ILLUMINA, INC: COMPANY SNAPSHOT (2021) 425
12.1.15 HOLOGIC, INC. 430
TABLE 310 HOLOGIC, INC: BUSINESS OVERVIEW 430
FIGURE 70 HOLOGIC, INC: COMPANY SNAPSHOT (2021) 431
12.2 OTHER PLAYERS 435
12.2.1 DEVYSER 435
TABLE 311 DEVYSER: BUSINESS OVERVIEW 435
FIGURE 71 DEVYSER: COMPANY SNAPSHOT (2021) 436
12.2.2 PERKINELMER INC. 438
TABLE 312 PERKINELMER, INC: BUSINESS OVERVIEW 438
FIGURE 72 PERKINELMER, INC: COMPANY SNAPSHOT (2021) 439
12.2.3 CHEMBIO DIAGNOSTICS, INC. 441
TABLE 313 CHEMBIO DIAGNOSTICS, INC: BUSINESS OVERVIEW 441
FIGURE 73 CHEMBIO DIAGNOSTICS, INC: COMPANY SNAPSHOT (2021) 442
12.2.4 SURMODICS, INC. 444
TABLE 314 SURMODICS, INC: BUSINESS OVERVIEW 444
FIGURE 74 SURMODICS, INC: COMPANY SNAPSHOT (2022) 445
12.2.5 MENARINI SILICON BIOSYSTEMS 447
TABLE 315 MENARINI SILICON BIOSYSTEMS: BUSINESS OVERVIEW 447
12.2.6 SPEEDX PTY. LTD. 448
12.2.7 GENSPEED BIOTECH GMBH 449
12.2.8 ACCELERATE DIAGNOSTICS, INC. 450
12.2.9 MERCK KGAA 451
12.2.10 CARIS LIFE SCIENCES, INC. 453
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 454
13.1 INSIGHTS FROM INDUSTRY EXPERTS 454
13.2 DISCUSSION GUIDE 455
13.3 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 461
13.4 CUSTOMIZATION OPTIONS 463
13.5 RELATED REPORTS 463
13.6 AUTHOR DETAILS 464

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 世界の体外診断（IVD）市場：製品＆サービス別（機器、キット、ソフトウェア）、技術別、用途別、エンドユーザー別(In Vitro Diagnostics Market by Product and Service (Instruments, Kits, Software), Technology (Immunoassay, Hematology, Urinalysis), Application (Diabetes, Oncology, Cardiology, Infectious Disease), End User (Hospitals, Clinics) - Forecast to 2027)]についてメールでお問い合わせはこちらでお願いします。

※関連リサーチレポートはありません。


◆H&Iグローバルリサーチのお客様（例）◆